Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec With or Without Metformin in Adults With Type 2 Diabetes (Onset® 9)

NCT03268005 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT03268005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03268005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec With or Without Metformin in Adults With Type 2 Diabetes (Onset® 9)
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
September 19, 2017
Completion date
January 29, 2019
Enrollment
1,264 (actual)
Sites
167

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2